Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis.
Farzana Yasmin ZamanAshwin SubramaniamAfsana AfrozZarka SamoonDaniel J GoughSurein ArulanandaMuhammad AlamgeerPublished in: Cancers (2023)
This large systematic review, despite heterogeneity, found that baseline negative ctDNA levels and early reduction in ctDNA following treatment could be strong prognostic markers for PFS and OS in patients undergoing targeted therapies for advanced NSCLC. Future randomised clinical trials should incorporate serial ctDNA monitoring to further establish the clinical utility in advanced NSCLC management.
Keyphrases
- circulating tumor
- clinical trial
- systematic review
- cell free
- small cell lung cancer
- circulating tumor cells
- patients undergoing
- advanced non small cell lung cancer
- open label
- meta analyses
- double blind
- single cell
- study protocol
- brain metastases
- current status
- randomized controlled trial
- placebo controlled
- epidermal growth factor receptor
- single molecule
- phase iii